标题
Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows
作者
关键词
-
出版物
Frontiers in Immunology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-08-13
DOI
10.3389/fimmu.2018.01668
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Paraoxonases and psoriasis: negative imbalance of antioxidant endogenous mechanisms
- (2019) Maria Schiattarella et al. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
- (2018) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future
- (2018) Annunziata Raimondo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors
- (2018) Rodolfo A. Kolliker Frers et al. Frontiers in Immunology
- Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
- (2018) Wolf-Henning Boehncke Frontiers in Immunology
- Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders
- (2017) Anna Balato et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin
- (2017) Masutaka Furue et al. INTERNAL MEDICINE
- Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment
- (2017) Stephen Hu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate
- (2017) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
- (2017) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials
- (2017) D. Wu et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- TNFα and its Receptors in Psoriatic Skin, before and after Treatment with Etanercept
- (2017) G. Caldarola et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis
- (2016) Jacek Karczewski et al. AUTOIMMUNITY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity
- (2016) Andrea Chiricozzi et al. Expert Review of Clinical Immunology
- Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study
- (2016) Spyridon Gkalpakiotis et al. JOURNAL OF DERMATOLOGY
- The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis
- (2016) Anna Campanati et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- IL-36γ Is Involved in Psoriasis and Allergic Contact Dermatitis
- (2016) Anna Balato et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results
- (2016) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Subclinical cardiovascular disease and it's improvement after long-term TNF-α inhibitor therapy in severe psoriatic patients
- (2016) E. Herédi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Association Between Psoriasis and Subclinical Atherosclerosis
- (2016) Na Fang et al. MEDICINE
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis
- (2016) Kasper Fjellhaugen Hjuler et al. JAMA Dermatology
- Cytokines in psoriasis
- (2015) Jaymie Baliwag et al. CYTOKINE
- Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities
- (2015) Caitriona Ryan et al. DERMATOLOGIC CLINICS
- Vitamin A Decreases Cytotoxicity of Oxidized Low-Density Lipoprotein in Patients with Atherosclerosis
- (2015) Mohammad Jafar Mahmoudi et al. IMMUNOLOGICAL INVESTIGATIONS
- Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink
- (2015) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study
- (2015) O. Ahlehoff et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study
- (2015) T. Pina et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin 23 Levels Are Increased in Carotid Atherosclerosis
- (2015) Azhar Abbas et al. STROKE
- CCL20andIL22Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis
- (2015) Ari M. Goldminz et al. JAMA Dermatology
- Atherosclerosis in psoriatic disease: latest evidence and clinical implications
- (2015) Lihi Eder et al. Therapeutic Advances in Musculoskeletal Disease
- Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease
- (2014) Susanne Karbach et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Point: Major adverse cardiovascular events and anti-IL 12/23 agents
- (2014) Thrasivoulos Tzellos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study
- (2014) T. Pina et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Vitamin A Supplementation Reduces IL-17 and RORc Gene Expression in Atherosclerotic Patients
- (2014) A. Mottaghi et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- IL-17 in psoriasis: Implications for therapy and cardiovascular co-morbidities
- (2013) Jackelyn B. Golden et al. CYTOKINE
- Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study
- (2013) O. Ahlehoff et al. JOURNAL OF INTERNAL MEDICINE
- Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis
- (2013) Eleanor J. Samarasekera et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses
- (2013) Erica D. Dommasch et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Association of ethnicity, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis
- (2013) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot study
- (2013) Hajnalka Jókai et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway
- (2013) A. Balato et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis
- (2013) Nehal N Mehta et al. Journal of Translational Medicine
- Metabolic syndrome and skin: Psoriasis and beyond
- (2013) Tanmay Padhi et al. INDIAN JOURNAL OF DERMATOLOGY
- Interleukin-12 Is Associated With Arterial Stiffness in Healthy Individuals
- (2012) K. Yong et al. AMERICAN JOURNAL OF HYPERTENSION
- Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
- (2012) Jashin J. Wu et al. ARCHIVES OF DERMATOLOGY
- Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis
- (2012) Robert Bissonnette et al. Circulation-Cardiovascular Imaging
- Cytokine-Based Therapy in Psoriasis
- (2012) Anupam Mitra et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction
- (2012) Tabassome Simon et al. EUROPEAN HEART JOURNAL
- Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease
- (2012) Ramin Ghazizadeh et al. International Journal of Medical Sciences
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
- (2012) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials
- (2012) T. Tzellos et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease
- (2011) Renata Micha et al. AMERICAN JOURNAL OF CARDIOLOGY
- The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study
- (2011) K. Abuabara et al. BRITISH JOURNAL OF DERMATOLOGY
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
- (2011) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) B.E. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) A.B. Gottlieb et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis and atherosclerosis: two plaques, one syndrome?
- (2011) A. J. Flammer et al. EUROPEAN HEART JOURNAL
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity
- (2011) Wolf-Henning Boehncke et al. EXPERIMENTAL DERMATOLOGY
- Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Thrasivoulos Tzellos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Caitriona Ryan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis
- (2011) Daniel H. Solomon JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- TNF alpha antagonist therapy and safety monitoring
- (2011) Thao Pham et al. JOINT BONE SPINE
- A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
- (2011) Kenneth B. Gordon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study
- (2011) S. Boehncke et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis
- (2011) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial
- (2010) Sandra Boehncke et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability
- (2010) Christian Erbel et al. BASIC RESEARCH IN CARDIOLOGY
- Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes
- (2010) Luis C.L. Correia et al. CLINICA CHIMICA ACTA
- Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters
- (2010) Manjula REDDY et al. JOURNAL OF DERMATOLOGY
- Emerging Role of IL-17 in Atherosclerosis
- (2010) Shuang Chen et al. Journal of Innate Immunity
- Psoriasis Is Not a Useful Independent Risk Factor for Cardiovascular Disease
- (2010) Robert S. Stern JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
- (2010) Batya B. Davidovici et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Interleukin-17 and Interferon-γ Are Produced Concomitantly by Human Coronary Artery–Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells
- (2009) Raymond E. Eid et al. CIRCULATION
- Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis
- (2009) Soraya Taleb et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Psoriasis May Not be an Independent Risk Factor for Acute Ischemic Heart Disease Hospitalizations: Results of a Large Population-Based Dutch Cohort
- (2009) Marlies Wakkee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
- (2009) Shinji Kagami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Inflammation in Atherosclerosis
- (2009) Peter Libby et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- The Th17/Treg imbalance in patients with acute coronary syndrome
- (2008) Xiang Cheng et al. CLINICAL IMMUNOLOGY
- Chronic Plaque Psoriasis Is Associated with Increased Arterial Stiffness
- (2008) Paolo Gisondi et al. DERMATOLOGY
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Lymphoid tissue inducer–like cells are an innate source of IL-17 and IL-22
- (2008) Hiroaki Takatori et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category
- (2008) Dror Luger et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti–tumour necrosis factor-α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study
- (2008) P Gisondi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started